Back

Antonio Bertoletti

Antonio Bertoletti, a professor at the Emerging Infectious Diseases programme, Duke-NUS Medical School.[1]Bertoletti is an expert in viral infections, particularly hepatitis B.[2]As part of the research, Bertoletti’s team studied T cell responses against the structural protein) and non-structural regions of SARS-CoV-2 in individuals convalescing from coronavirus disease 2019.[3]In a 2011 article published in the Journal of Virology , Bertoletti led a team that generated TCR-T cells that can go after SARS, another coronavirus that caused a deadly outbreak in China and other countries in late 2002 and early 2003.[4]The human hepatoma cell line HepG2-core, stably transduced with HBcAg, was provided by Dr. Bertoletti.[5]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Antonio Bertoletti on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Employer

  • 5

    Events

  • 140

    Mentions

  • 127

    Docs

Recent events

In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo

Retroviral transduction of primary human T cells To generate CAR-transduced or TCR-transduced T cells, human CD8+ T cells were stimulated with antiCD3/CD28-coated Dynabeads for 48 h at a bead-to-cell ratio of 1:1 in the presence of 30 U/mL rIL-2. Nanoparticle preparation mRNA stocks were diluted to 100 µg/mL in 25 mM nuclease-free sodium acetate buffer, pH 5.2.[5]

11/26/2020

Event Date

Covid-19 antibodies last at least three months after infection

“Our study shows that IgG antibodies against the virus’ tip protein are relatively long-lasting in both blood and saliva. Most people who recover from COVID-19 develop immune agents called antibodies specific to the virus in their blood. Although this team of researchers admit that there is much they do not yet know about antibody responses to SARS-CoV-2 infection, including how long the antibodies last beyond this period or what protection they offer against re-infection, this Research could have broader implications in the development of an effective vaccine.[6]

10/11/2020

Event Date

Immune T-cells may offer long-lasting protection against COVID-19. Scientists found some coronavirus patients recovered from COVID-19 infection due to the presence of T-cell immunity

Back in January before the widespread of the coronavirus pandemic, we wrote a piece about how researchers at Cardiff University may have found a cure for cancer after the team of researchers accidentally discovered immune cell that kills most cancers. For months, much of the study on the immune response to SARS-CoV-2, the virus that causes COVID-19, has focused on the production of antibodies. Now, researchers are conducting an extensive study on a different type of immune cells known as memory T cells.[3]

09/24/2020

Event Date